UNIONDALE, NY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be participating in Renmark Financial Communications Inc’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, September 4, 2025, at 12:00 pm EDT. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event.
The presentation will feature Ted Karkus, Chairman and Chief Executive Officer. Topics to be covered will include a general overview of the Company as well as several important initiatives including the crypto treasury strategy, potential significant liquidity events that are well underway and the cancellation of the Equity Line of Credit (ELOC). The investor presentation will be followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Company’s Investor website.
Thursday, September 4, 2025:
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Retail Investor Relations Contact:
Renmark Financial Communications Inc.
John Boidman: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
| Last Trade: | US$0.47 |
| Daily Change: | -0.04 -7.60 |
| Daily Volume: | 1,297,396 |
| Market Cap: | US$19.610M |
September 23, 2025 August 13, 2025 August 12, 2025 June 17, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
